ES2173185T3 - Empleo de derivados de tetrahidropteridina como inhibidores de la no-sintasa. - Google Patents

Empleo de derivados de tetrahidropteridina como inhibidores de la no-sintasa.

Info

Publication number
ES2173185T3
ES2173185T3 ES95921745T ES95921745T ES2173185T3 ES 2173185 T3 ES2173185 T3 ES 2173185T3 ES 95921745 T ES95921745 T ES 95921745T ES 95921745 T ES95921745 T ES 95921745T ES 2173185 T3 ES2173185 T3 ES 2173185T3
Authority
ES
Spain
Prior art keywords
inhibitors
employment
synthase
radical
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95921745T
Other languages
English (en)
Inventor
Wolfgang Pfleiderer
Harald Schmidt
Rainer Henning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verinos Operations GmbH
Original Assignee
Vasopharm Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasopharm Biotech GmbH filed Critical Vasopharm Biotech GmbH
Application granted granted Critical
Publication of ES2173185T3 publication Critical patent/ES2173185T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA PRESENTE INVENCION TRATA DE LA UTILIZACION DE DERIVADOS DE PTERIDINA DE FORMULA GENERAL (I), ENLA QUE X ES O O NH Y R{SUP,4} ES P. E. HIDROGENO, FENILO O EL RADICAL R{SUP,4A}-CH{SUB,2}- Y R{SUP,4A} ES P. E. HIDROGENO, MERCAPTOALQUILO DE C{SUB,1}C{SUB,4}, EL RADICAL -NR{SUP,11}R{SUP,12} O EL RADICAL OR{SUP,13}, Y R{SUP,1}, R{SUP,2}, R{SUP,3}, R{SUP,5}, R{SUP,6}, R{SUP,7}, R{SUP,11}, R{SUP,12} Y R{SUP,13} TIENEN LOS SIGNIFICADOS DADOS EN LA REIVINDICACION 1; SON INHIBIDORES DE LA SINTETASA DEL MONOXIDO DE NITROGENO, PAA EL TRATAMIENTO DE ENFERMEDADES, QUE ESTAN CAUSADAS POR UN ELEVADO NIVEL DE MONOXIDO DE NITROGENO.
ES95921745T 1994-05-24 1995-05-11 Empleo de derivados de tetrahidropteridina como inhibidores de la no-sintasa. Expired - Lifetime ES2173185T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4418097A DE4418097A1 (de) 1994-05-24 1994-05-24 Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase

Publications (1)

Publication Number Publication Date
ES2173185T3 true ES2173185T3 (es) 2002-10-16

Family

ID=6518842

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95921745T Expired - Lifetime ES2173185T3 (es) 1994-05-24 1995-05-11 Empleo de derivados de tetrahidropteridina como inhibidores de la no-sintasa.

Country Status (8)

Country Link
US (1) US6858612B1 (es)
EP (1) EP0760818B1 (es)
JP (1) JP4287506B2 (es)
AT (1) ATE214068T1 (es)
DE (2) DE4418097A1 (es)
ES (1) ES2173185T3 (es)
PT (1) PT760818E (es)
WO (1) WO1995032203A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU688811B2 (en) * 1993-10-21 1998-03-19 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
DE4418097A1 (de) 1994-05-24 1995-11-30 Cassella Ag Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase
ES2206571T3 (es) * 1995-04-20 2004-05-16 G.D. SEARLE & CO. Agentes de amidino ciclico utiles como inhibidores de la oxido nitrico sintasa.
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
JP4842415B2 (ja) * 1996-08-30 2011-12-21 第一三共株式会社 Ｎｏｓの機能低下が寄与する疾患の予防または治療剤
DE69725721T3 (de) † 1996-08-30 2007-10-31 Daiichi Asubio Pharma Co., Ltd. Vorbeugende oder heilende mittel für krankheiten, die durch mangel an stickoxid-synthase (nos) ausgelöst sind
US5922713A (en) * 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
ATE201412T1 (de) * 1997-10-06 2001-06-15 Ernst Werner Pteridinderivate als no synthase-hemmer
CA2333691A1 (en) 1998-06-10 1999-12-16 G.D. Searle & Co. Heterobicyclic and tricyclic nitric oxide synthase inhibitors
DE59805976D1 (de) * 1998-07-10 2002-11-21 Ernst Werner Herstellung eines die Transplantatabstossung unterdrückenden Mittels
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
AU770551B2 (en) * 1998-12-28 2004-02-26 4-Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
EP1199078A1 (en) * 1999-06-09 2002-04-24 Ono Pharmaceutical Co., Ltd. Analgesics
DE19944767A1 (de) 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
JP4836388B2 (ja) * 2002-03-22 2011-12-14 第一三共株式会社 ｅＮＯＳ発現に起因する疾患の予防または治療薬
DE10260263A1 (de) * 2002-12-20 2004-07-15 Biocrates Life Sciences Gmbh Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen
WO2005037286A1 (en) 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
JP2007509909A (ja) * 2003-10-31 2007-04-19 アルタナ　ファルマ　アクチエンゲゼルシャフト 呼吸器疾患の治療のためのｂｈ４の使用
US7541360B2 (en) 2003-12-30 2009-06-02 Vasopharm Gmbh 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level
US20060194800A1 (en) * 2005-01-07 2006-08-31 University Of Strathclyde Pteridine derivatives as nitric oxide synthase activators
US20090075992A1 (en) * 2005-01-07 2009-03-19 University Of Strathclyde Pteridine Derivatives as Nitric Oxide Synthase Activators
JP2008540486A (ja) * 2005-05-11 2008-11-20 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビター及びテトラヒドロビオプテリン誘導体との組合せ物
WO2008009079A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
CA2675134A1 (en) * 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Pterin analogs
US9849027B2 (en) 2007-11-08 2017-12-26 Alimera Sciences, Inc. Ocular implantation device
USD592746S1 (en) 2007-11-08 2009-05-19 Alimera Sciences Ocular implantation device
AU2008347005B2 (en) 2008-01-03 2013-10-03 Biomarin Pharmaceutical Inc. Pterin analog for treating BH4 responsive condition
SG11201606876RA (en) 2015-03-04 2016-10-28 Gilead Sciences Inc Toll like receptor modulator compounds
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
SI3507276T1 (sl) 2016-09-02 2022-01-31 Gilead Sciences, Inc. Spojine modulatorja toličnih receptorjev
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN114984019B (zh) * 2022-07-15 2023-08-22 山东中医药大学 一种铁死亡抑制剂化合物及在肝损伤修复领域的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8318833D0 (en) 1983-07-12 1983-08-10 Wellcome Found Chemical compounds
JPS5976086A (ja) 1982-09-20 1984-04-28 ザ　ウエルカム　フアウンデ−シヨン　リミテツド プテリジン化合物
US5196533A (en) 1983-04-11 1993-03-23 South Alabama Medical Science Foundation, Usa Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines
US4937342A (en) 1987-11-30 1990-06-26 Kabushiki Kaisha Vitamin Kenkyusyo Intermediates for synthesizing BH4 and its derivatives
JPH0656669A (ja) * 1992-06-11 1994-03-01 Asahi Breweries Ltd 活性酸素消去作用を持つプテリン誘導体製剤
EP0674627A1 (en) * 1992-12-18 1995-10-04 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5502050A (en) 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
DE4418097A1 (de) 1994-05-24 1995-11-30 Cassella Ag Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase
US5753656A (en) 1994-08-05 1998-05-19 Suntory Limited Method for treating spinocerebellar degeneration

Also Published As

Publication number Publication date
WO1995032203A2 (de) 1995-11-30
WO1995032203A3 (de) 1995-12-28
PT760818E (pt) 2002-08-30
JP4287506B2 (ja) 2009-07-01
DE4418097A1 (de) 1995-11-30
EP0760818B1 (de) 2002-03-06
EP0760818A1 (de) 1997-03-12
US6858612B1 (en) 2005-02-22
JPH10500417A (ja) 1998-01-13
DE59510094D1 (de) 2002-04-11
ATE214068T1 (de) 2002-03-15

Similar Documents

Publication Publication Date Title
PT760818E (pt) Utilizacao de derivados de tetra-hidropteridina como inibidores da no-sintase
ES2180633T3 (es) Uso de derivados de pteridina como inhibidores de la no-sintasa.
ATE324895T1 (de) Purin-derivate zur behandlung allgischer erkrankungen und systemischem lupus erythematodes
CA2290506A1 (en) 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
DE59803845D1 (de) Sulfinsäurederivate und deren herstellung und verwendung
TR200402157T2 (tr) Heteroaril süksinamidler ve metalloproteinaz inhibitörü olarak kullanımları
TR200100411T2 (tr) 2-(Pürin-9-il)-tetrahidrofuran-3,4-diol türevleri.
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DE69912606D1 (de) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivate
EA199900448A1 (ru) Производные 6-фенилпиридил-2-амина, полезные в качестве ингибиторов nos
PT839154E (pt) Peptidos e composicoes biologicamente activos sua utilizacao
ATE65994T1 (de) Insektentoetende pyrazoline.
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
BRPI9916096B8 (pt) derivados de bacterioclorofila substituídos com paládio, processos para sua preparação, composição compreendendo esses derivados e seu uso.
BR9712140A (pt) Agentes e processos para inibir a produção de citoquina, a adesão de cédulas e a produção de tnf - alfa e uso de um composto.
NO994330L (no) Metode for behandling av en tumor
EA200000204A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
DE59403966D1 (de) Hydroxymethylfurazancarbonsäurederivate und ihre verwendung in der behandlung von kardiovaskulären erkrankungen
DE69928282D1 (de) Substituierte 1,3,5-triazine als herbizide
DE59509727D1 (de) Uracilderivate
ES8604853A1 (es) Un metodo para la preparacion de un derivado de acetileno.
MX9701764A (es) Derivados de imidoacidos.
DK1104419T3 (da) N-substituerede azabicyloheptan-derivater, deres fremstilling og anvendelse
UA26982A1 (uk) Похідhі малоhової кислоти, які проявляють властивості іhгібітору росту рослиh

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 760818

Country of ref document: ES